A diagnostic dilemma in a patient receiving antiretroviral and antituberculosis therapy

AIDS Reader

Volumn 15, Issue 2, 2005, Pages 72-75

  Vallabhaneni, Snigdha ^a   Kumarasamy, Nagalingeswaran ^b   Wing, Edward J ^a   Flanigan, Timothy P ^a  

^a BROWN UNIVERSITY   (United States)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

Coinfection; Developing countries; HIV AIDS; Immune reconstitution syndrome; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEVELOPING COUNTRY; DISEASE EXACERBATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; INDIA; LUNG INFILTRATE; LUNG TUBERCULOSIS; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; PRACTICE GUIDELINE; AIDS RELATED COMPLEX; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; METHODOLOGY; RISK ASSESSMENT; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MALE; RADIOGRAPHY, THORACIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 14544305154     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363.
2. + T cell-homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
3. Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999;13: 2105-2111.
4. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213-227.
5. Kumarasamy N, Solomon S, Flanigan T, et al. Natural history of human immunodeficiency virus infection in southern India. Clin Infect Dis. 2003;36:79-85.
6. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-686.
7. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV-TB co-infected patients after initiation of generic HAART in India. J Acquir Immune Defic Syndr. 2004; 37:1574-1576.
8. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158:157-161.
9. Buckingham SJ, Haddow LJ, Shaw PJ, Miller KF. Immune reconstitution inflammatory syndrome in HIV-iniected patients with mycobacterial infections starting highly active anti-retroviral therapy. Clin Radiol. 2004;59:505-513.
10. Scaling Up Anttretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2003.
11. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis. 2002;34:224-233.
12. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159-1166.